

# Viktar M Mitsura

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2609630/publications.pdf>

Version: 2024-02-01

75  
papers

3,406  
citations

218677

26  
h-index

144013

57  
g-index

75  
all docs

75  
docs citations

75  
times ranked

4100  
citing authors

#	ARTICLE	IF	CITATIONS
1	Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021, 22, 283-293.	2.2	6
2	Molecular and genetic properties of hepatitis b virus and their clinical role in chronic hepatitis B. <i>HIV Infection and Immunosuppressive Disorders</i> , 2021, 12, 43-50.	0.3	1
3	Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. <i>Aids</i> , 2021, 35, 2025-2033.	2.2	4
4	Risk for Non-AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 768-776.	3.9	14
5	The diagnostic value of indirect markers of liver fibrosis in patients with chronic hepatitis B. <i>Jurnal Infektologii</i> , 2020, 12, 73-79.	0.3	0
6	Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study – 2012 – 2015. <i>PLoS ONE</i> , 2019, 14, e0220108.	2.5	31
7	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1224-1228.	2.0	15
8	People who inject drugs remain hard-to-reach population across all HIV continuum stages in Central, Eastern and South Eastern Europe – data from Euro-guidelines in Central and Eastern Europe Network. <i>Infectious Diseases</i> , 2019, 51, 277-286.	2.8	20
9	Establishing a hepatitis C continuum of care among HIV/hepatitis C virus co-infected individuals in EuroSIDA. <i>HIV Medicine</i> , 2019, 20, 264-273.	2.2	9
10	Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe. <i>Aids</i> , 2019, 33, 2013-2024.	2.2	13
11	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. <i>Aids</i> , 2019, 33, 327-337.	2.2	5
12	HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. <i>BMC Medicine</i> , 2019, 17, 4.	5.5	43
13	State of viral hepatitis care in 16 countries of Central and Eastern European Region. <i>Central European Journal of Public Health</i> , 2019, 27, 212-216.	1.1	6
14	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018, 19, 324-338.	2.2	4
15	Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. <i>Journal of the International AIDS Society</i> , 2018, 21, e25031.	3.0	38
16	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. <i>HIV Medicine</i> , 2018, 19, 252-260.	2.2	2
17	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV-HBV-Coinfected Patients in the EuroSIDA Study. <i>Antiviral Therapy</i> , 2018, 23, 405-413.	1.0	5
18	Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2018, 5, e211-e220.	4.7	108

#	ARTICLE	IF	CITATIONS
19	Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. <i>AIDS and Behavior</i> , 2018, 22, 1573-1583.	2.7	32
20	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. <i>Journal of Infection</i> , 2018, 76, 44-54.	3.3	16
21	Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. <i>HIV Medicine</i> , 2018, 19, 102-117.	2.2	6
22	The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. <i>HIV Medicine</i> , 2018, 19, 90-101.	2.2	14
23	Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV-positive patients with well-estimated dates of seroconversion. <i>HIV Medicine</i> , 2018, 19, 184-194.	2.2	41
24	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , 2018, 32, 161-169.	2.2	19
25	Antiretroviral pill count and clinical outcomes in treatment-naïve patients with HIV infection. <i>HIV Medicine</i> , 2018, 19, 132-142.	2.2	8
26	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018, 32, 205-215.	2.2	5
27	HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. <i>HIV Medicine</i> , 2018, 19, 33-41.	2.2	15
28	Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. <i>Aids</i> , 2018, 32, 1995-2004.	2.2	24
29	HIV health care providers are ready to introduce pre-exposure prophylaxis in Central and Eastern Europe and neighbouring countries: data from the Euroguidelines in Central and Eastern Europe (ECEE) Network Group. <i>HIV Medicine</i> , 2018, 19, 629-633.	2.2	8
30	Scale-up of HIV self-testing. <i>HIV Medicine</i> , 2018, 19, e72.	2.2	7
31	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. <i>HIV Medicine</i> , 2018, 19, 42-48.	2.2	8
32	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. <i>Eurosurveillance</i> , 2018, 23, .	7.0	12
33	RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS. <i>Jurnal Infektologii</i> , 2018, 10, 77-83.	0.3	1
34	Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, e74-e83.	2.1	23
35	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	4.0	20
36	Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration – a comprehensive meeting report. <i>HIV Medicine</i> , 2017, 18, 370-375.	2.2	19

#	ARTICLE	IF	CITATIONS
37	Reference curves for <sc>CD</sc>4 Tâ€cell count response to combination antiretroviral therapy in <sc>HIV</sc>â€1â€infected treatmentâ€naÃve patients. HIV Medicine, 2017, 18, 33-44.	2.2	16
38	One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. Aids, 2017, 31, 375-384.	2.2	5
39	DECOLONIZATION OF INTESTINAL CARRIAGE OF MDR/XDR GRAM-NEGATIVE BACTERIA WITH ORAL COLISTIN IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, 2018030.	1.3	10
40	Reduction in undiagnosed HIV infection in the European Union/European Economic Area, 2012 to 2016. Eurosurveillance, 2017, 22, .	7.0	12
41	Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression. Medicine (United States), 2016, 95, e5020.	1.0	2
42	Infectionâ€related and â€unrelated malignancies, <sc>HIV</sc> and the aging population. HIV Medicine, 2016, 17, 590-600.	2.2	37
43	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV,the, 2016, 3, e120-e131.	4.7	53
44	Major differences in organization and availability of health care and medicines for <sc>HIV/TB</sc> coinfecting patients across <sc>E</sc>urope. HIV Medicine, 2015, 16, 544-552.	2.2	19
45	Liver-related death among HIV/hepatitis C virus-co-infected individuals. Aids, 2015, 29, 1205-1215.	2.2	46
46	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809.	8.4	119
47	Hepatitis C seroconversions in <sc>HIV</sc> infection across Europe: which regions and patient groups are affected?. Liver International, 2015, 35, 2384-2391.	3.9	33
48	Changing utilization of Stavudine (d4T) in HIVâ€positive people in 2006â€2013 in the EuroSIDA study. HIV Medicine, 2015, 16, 533-543.	2.2	11
49	Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study. PLoS ONE, 2015, 10, e0140845.	2.5	43
50	Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression. Journal of the International AIDS Society, 2014, 17, 19810.	3.0	7
51	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. European Respiratory Journal, 2014, 43, 166-177.	6.7	30
52	Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. Aids, 2014, 28, 2565-2571.	2.2	9
53	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection, 2014, 42, 757-762.	4.7	4
54	Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis. Aids, 2014, 28, 577-587.	2.2	11

#	ARTICLE	IF	CITATIONS
55	Deteriorating renal function and clinical outcomes in HIV-positive persons. <i>Aids</i> , 2014, 28, 727-737.	2.2	25
56	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160.	2.5	35
57	Health care index score and risk of death following tuberculosis diagnosis in HIV-positive patients. <i>International Journal of Tuberculosis and Lung Disease</i> , 2013, 17, 198-206.	1.2	7
58	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. <i>BioMed Research International</i> , 2013, 2013, 1-9.	1.9	10
59	Predictors of CD4+ T-Cell Counts of HIV Type 1 "Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. <i>Journal of Infectious Diseases</i> , 2013, 207, 759-767.	4.0	7
60	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. <i>BMC Infectious Diseases</i> , 2013, 13, 471.	2.9	68
61	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.	2.5	25
62	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.5	145
63	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. <i>Aids</i> , 2012, 26, 1917-1926.	2.2	62
64	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673.	2.5	32
65	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.	4.0	19
66	Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 582-589.	2.1	42
67	Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. <i>Aids</i> , 2010, 24, 1667-1678.	2.2	353
68	Variable Impact on Mortality of AIDS "Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS "Defining Conditions Are Created Equal. <i>Clinical Infectious Diseases</i> , 2009, 48, 1138-1151.	5.8	108
69	Loss to follow "up in an international, multicentre observational study. <i>HIV Medicine</i> , 2008, 9, 261-269.	2.2	91
70	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. <i>Aids</i> , 2008, 22, 2143-2153.	2.2	207
71	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , 2008, 22, 367-376.	2.2	43
72	Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 607-615.	2.1	47

#	ARTICLE	IF	CITATIONS
73	Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor-Containing cART Regimens in Antiretroviral-Naïve Patients Starting cART After January 1, 2000. HIV Clinical Trials, 2006, 7, 271-284.	2.0	6
74	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. Archives of Internal Medicine, 2006, 166, 1632.	3.8	1,004
75	Reversible Spatial Filter Of The Type "Photosensitive Organic Polymer - Liquid Crystal" For Holographic Application. , 1990, 1183, 28.		1